INAPSINE INJ 2.5MG/ML DIN 00554251
Status: Cancelled Post Market
Holder: JANSSEN PHARMACEUTICA, DIVISION OF JANSSEN-ORTHO INC.
Molecule: DROPERIDOL
Health Canada record
| Active ingredient(s) | DROPERIDOL 2.5 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intramuscular; Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N01AX01 DROPERIDOL |
| Original market date | 31-Dec-1982 |
| Current status date | 10-Aug-1998 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Pharmaceutica — licence , not currently licensed, last inspection rating C (2025-05-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DROPERIDOL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02232449 | DROPERIDOL INJECTION | NOVOPHARM LIMITED | Liquid | DROPERIDOL 2.5 MG | Cancelled Post Market |
| 02167832 | DROPERIDOL INJECTION USP 2.5MG/ML | SANDOZ CANADA INCORPORATED | Solution | DROPERIDOL 2.5 MG | Cancelled Post Market |
International API supply for DROPERIDOL
1 valid EDQM Certificates of Suitability from 1 holders. 2 active FDA Drug Master Files.
Request a quote for INAPSINE INJ 2.5MG/ML